TABLE 1

Patient and Healthy Control Data

Subject	Sex	Age (y)	Ischemic heart disease	Diagnosis	Melphalan^*	IVSd^† (cm)	Posterior wall thickness (cm)	RV^‡ (cm)	E/e^§	LV ejection fraction	LV end-diastolic volume (mL)	Left atrial volume (mL m⁻²)	RI for ¹¹C-PIB (min⁻¹)	MBF (mL cm⁻³ min⁻¹)
1	M	55	No	Transthyretin^∥	No	1.7	1.7	0.8	17	0.54	83	34	0.071	0.59
2	F	63	Yes	AL κ	Yes	1.6	1.3	0.5	22	0.56	46	41	0.075	0.72
3	M	71	No	Transthyretin^¶	No	2.0	1.6	0.7	15	0.43	75	40	0.033	0.24
4	M	63	No	AL λ	Yes	1.9	1.6	0.5	—	0.44	152	45	0.036	0.33
5	M	75	Yes	AL λ	No	1.7	1.6	0.5	10	0.42	82	74	0.048	0.52
6	M	48	No	AL λ	Yes	1.8	1.7	0.7	11	0.66	98	38	0.042	0.54
7	M	67	No	AL κ	Yes	1.3	1.5	0.4	21	0.67	84	56	0.039	0.47
8	M	65	No	Transthyretin^‡	No	2.2	2.1	1.2	29	0.48	58	33	0.033	0.34
9	M	76	No	AL λ	No	1.5	1.4	0.7	20	0.42	80	48	0.134	0.46
10	M	77	No	AL λ	Yes	1.5	1.5	0.6	—	0.64	95	52	0.033	0.52
11	M	75	No	Healthy	No								0.020	0.60
12	F	71	No	Healthy	No								0.023	1.08
13	M	60	No	Healthy	No								0.029	0.63
14	M	61	No	Healthy	No								0.031	0.74
15	F	54	No	Healthy	No								0.023	0.52

↵* Antiamyloid treatment before PET.
↵† Interventricular septal wall thickness in diastole.
↵‡ Thickness of right ventricular free wall.
↵§ Ratio of E-wave deceleration time and septal wall motion at time of early mitral flow.
↵∥ Familial Val30Met transthyretin.
↵¶ Senile systemic amyloidosis.